NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed
Clinical Trials
13 trialsNCT05275374 2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2 Not yet recruiting
NCT02858921 2023-08-30
Neo Trio
Melanoma Institute Australia
Phase 2 Unknown
NCT02083354 2022-02-01
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis
Phase 2 Completed
NCT02110355 2021-03-26
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Kartos Therapeutics, Inc.
Phase 1 Completed
NCT01597908 2021-02-24
COMBI-v
Novartis
Phase 3 Completed
NCT01072175 2019-07-05
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
Novartis
Phase 2 Completed
NCT02314143 2019-02-18
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
GlaxoSmithKline
Phase 2 Terminated
NCT02065063 2018-06-01
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01245062 2018-04-05
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
GlaxoSmithKline
Phase 3 Completed
NCT01328106 2017-12-12
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
GlaxoSmithKline
Phase 2 Withdrawn
NCT00687622 2017-11-13
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
GlaxoSmithKline
Phase 1 Completed
NCT01037127 2014-03-31
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
GlaxoSmithKline
Phase 2 Completed